Published in Immunology on February 01, 1993
Eosinophils in the pathogenesis of allergic airways disease. Cell Mol Life Sci (2007) 1.26
Involvement of prostaglandins in the down-regulation of allergic plasma leakage observed in rats undergoing pleural eosinophilia. Br J Pharmacol (1996) 0.76
Lack of Platelet-Activating Factor Receptor Attenuates Experimental Food Allergy but Not Its Metabolic Alterations regarding Adipokine Levels. Biomed Res Int (2016) 0.75
Lactic dehydrogenase activity in blood. Proc Soc Exp Biol Med (1955) 13.98
Platelet-activating factor. A potent chemotactic and chemokinetic factor for human eosinophils. J Clin Invest (1986) 2.90
Cytotoxic effects of the guinea pig eosinophil major basic protein on tracheal epithelium. Lab Invest (1980) 2.70
Effects of inhaled platelet activating factor on pulmonary function and bronchial responsiveness in man. Lancet (1986) 2.41
Inflammatory mediators and asthma. Pharmacol Rev (1988) 2.17
Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis (1989) 2.08
Basophils in bronchial asthma with reference to reagin-type allergy. Clin Allergy (1973) 1.86
Role of the eosinophil in the allergic reactions. II. Release of prostaglandins from human eosinophilic leukocytes. J Immunol (1975) 1.71
Studies on the adhesive interaction between purified human eosinophils and cultured vascular endothelial cells. J Immunol (1988) 1.68
Prostaglandin D2 potentiates airway responsiveness to histamine and methacholine. Am Rev Respir Dis (1986) 1.65
Airway hyperresponsiveness induced by platelet-activating factor: role of thromboxane generation. J Pharmacol Exp Ther (1986) 1.62
Increased biosynthesis of platelet-activating factor in activated human eosinophils. J Biol Chem (1984) 1.61
Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest (1991) 1.60
The eosinophil as a mediator of damage to respiratory epithelium: a model for bronchial hyperreactivity. J Allergy Clin Immunol (1988) 1.53
Human eosinophil major basic protein causes hyperreactivity of respiratory smooth muscle. Role of the epithelium. Am Rev Respir Dis (1988) 1.52
Effect of platelet-activating factor on airway vascular permeability: possible mechanisms. J Appl Physiol (1985) (1987) 1.50
Synthesis and release of leukotriene C4 by human eosinophils. J Immunol (1987) 1.47
Induction of bronchial hypersensitivity: evidence for a role for prostaglandins. Thorax (1981) 1.34
Increased numbers of hypodense eosinophils in the blood of patients with bronchial asthma. Am Rev Respir Dis (1985) 1.32
Stimulation of degranulation from human eosinophils by platelet-activating factor. J Immunol (1989) 1.32
Ultrastructural evidence for extravascular platelet recruitment in the lung upon intravenous injection of platelet-activating factor (PAF-acether) to guinea-pigs. Br J Exp Pathol (1985) 1.12
Skin eosinophilia in atopic patients. J Allergy Clin Immunol (1988) 1.11
Inhibition of antigen-induced airway hyperresponsiveness by a thromboxane synthetase inhibitor (OKY-046) in allergic dogs. Am Rev Respir Dis (1986) 1.09
Microvascular leakage to platelet activating factor in guinea-pig trachea and bronchi. Eur J Pharmacol (1987) 1.04
The bronchoconstrictor properties of platelet-activating factor in humans. Am Rev Respir Dis (1987) 1.04
Noncytotoxic activation of neutrophils by eosinophil granule major basic protein. Effect on superoxide anion generation and lysosomal enzyme release. J Immunol (1990) 1.02
Time-dependent effect of prostaglandin E2 inhalation on airway responses to bronchoconstrictor agents in normal subjects. Thorax (1982) 0.99
Acute effects of intratracheal administration of platelet-activating factor in baboons. J Appl Physiol Respir Environ Exerc Physiol (1983) 0.97
Effects of a thromboxane synthetase inhibitor (OKY-046) and a lipoxygenase inhibitor (AA-861) on bronchial responsiveness to acetylcholine in asthmatic subjects. Thorax (1986) 0.97
The effects of activated eosinophils and neutrophils on guinea pig airway epithelium in vitro. Am J Respir Cell Mol Biol (1990) 0.94
Transformation of prostaglandin D2 to isomeric prostaglandin F2 compounds by human eosinophils. A potential mast cell-eosinophil interaction. J Immunol (1988) 0.93
Preferential human eosinophil chemotactic activity of the platelet-activating factor (PAF) 1-0-hexadecyl-2-acetyl-sn-glyceryl-3-phosphocholine (AGEPC). J Clin Immunol (1987) 0.92
Platelet-activating factor induces eosinophil peroxidase release from purified human eosinophils. Immunology (1988) 0.91
Airway responses to sequential challenges with platelet-activating factor and leukotriene D4 in rhesus monkeys. J Lab Clin Med (1984) 0.87
The role of the eosinophilic leukocyte in bronchial asthma. Bull Eur Physiopathol Respir (1986) 0.87
Interactions between granulocytes and platelets with the guinea-pig lung in passive anaphylactic shock. Correlations with PAF-acether-induced lesion. Int Arch Allergy Appl Immunol (1987) 0.85
Platelet activating factor stimulates cyclo-oxygenase activity in guinea pig eosinophils. Concerted biosynthesis of thromboxane A2 and E-series prostaglandins. J Immunol (1990) 0.84
Human peritoneal eosinophils and formation of arachidonate cyclooxygenase products. Scand J Immunol (1986) 0.82
Platelet-activating factor induces leukotriene C4 synthesis by purified human eosinophils. Prostaglandins (1987) 0.82
Prejunctional control of excitatory neuroeffector transmission by prostaglandins in the airway smooth muscle tissue. Am Rev Respir Dis (1991) 0.81
Does airway smooth muscle care about platelet-activating factor? Eur Respir J (1992) 0.77
Flow-cytometric analysis of increased IgE uptake by normal eosinophils following activation with PAF-acether and other inflammatory mediators. Int Arch Allergy Appl Immunol (1989) 0.77
Density heterogeneity of eosinophil leucocytes: induction of hypodense eosinophils by platelet-activating factor. Immunology (1989) 0.76
T-lymphocytosis in bronchoalveolar lavage fluid of hypersensitivity pneumonitis. Changes in profile of T-cell subsets during the course of disease. Chest (1984) 1.50
Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis (1990) 1.47
Effect of a specific cysteinyl leukotriene-receptor 1-antagonist (montelukast) on the transmigration of eosinophils across human umbilical vein endothelial cells. Clin Exp Allergy (2001) 1.45
Ia-like antigens on T-cells and their subpopulations in pulmonary sarcoidosis and in hypersensitivity pneumonitis. Analysis of bronchoalveolar and blood lymphocytes. Am Rev Respir Dis (1985) 1.42
[Guidelines to long-term oxygen therapy]. Pneumologie (2001) 1.41
Satuation exposures at 31 ATA in an oxygen-helium atmosphere with excursions to 36 ATA. Aerosp Med (1970) 1.39
[Established combinations of inhaled corticoids and long-acting beta 2-symphathomimetics for long-term therapy of bronchial asthma. Position of an expert panel study]. Pneumologie (1999) 1.38
T cells and cytokines in bronchoalveolar lavage fluid after segmental allergen provocation in atopic asthma. Am J Respir Crit Care Med (1995) 1.29
Endobronchial secretion of interleukin-13 following local allergen challenge in atopic asthma: relationship to interleukin-4 and eosinophil counts. Eur Respir J (1996) 1.21
Th1 cytokine pattern in sarcoidosis is expressed by bronchoalveolar CD4+ and CD8+ T cells. Clin Exp Immunol (2000) 1.13
New method for easy labeling of beta-2-agonists in the metered dose inhaler with technetium 99m. Respiration (1988) 1.11
[Adhesion receptors: pathophysiologic, diagnostic and therapeutic importance]. Med Klin (Munich) (1993) 1.07
Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl (1986) 1.06
Alterations in immunoregulatory T-cell subsets in cigarette smokers. A phenotypic analysis of bronchoalveolar and blood lymphocytes. Chest (1986) 1.04
Predictive value of bronchoalveolar T cell subsets for the course of pulmonary sarcoidosis. Ann N Y Acad Sci (1986) 1.03
Symbols, abbreviations and units. Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Eur Respir J Suppl (1993) 1.00
Dextromethorphan and codeine: objective assessment of antitussive activity in patients with chronic cough. J Int Med Res (1983) 0.98
Mechanism of membrane damage mediated by eosinophil major basic protein. Lancet (1987) 0.98
Inflammatory determinants of asthma severity: mediator and cellular changes in bronchoalveolar lavage fluid of patients with severe asthma. J Allergy Clin Immunol (1996) 0.96
Mucociliary clearance in smokers. Eur J Respir Dis (1986) 0.95
Synergistic effects of interleukin-4 or interleukin-13 and tumor necrosis factor-alpha on eosinophil activation in vitro. Am J Respir Cell Mol Biol (1999) 0.93
Increase in perforin-positive peripheral blood lymphocytes in extrinsic and intrinsic asthma. Am J Respir Crit Care Med (2000) 0.92
Comparative measurements of airway resistance. Respiration (1975) 0.92
Lung and blood lymphocyte subsets in asbestosis and in mixed dust pneumoconiosis. Chest (1987) 0.91
The pattern of flow in the upper human airways. Respir Physiol (1968) 0.89
Effects of interferon-gamma and tumour necrosis factor-alpha on CD95/Fas ligand-mediated apoptosis in human blood eosinophils. Scand J Immunol (2000) 0.88
Pulmonary immune cells in health and disease: the eosinophil leucocyte (Part II). Eur Respir J (1994) 0.86
Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol (1996) 0.86
[The influence of beta-adrenergic stimulation on the mucociliary system of the human lung (author's transl)]. Pneumonologie (1975) 0.86
[Cytologic and immunocytologic findings in bronchoalveolar lavage as a contribution to the differential diagnosis of chronic lung hemorrhage]. Pneumologie (1990) 0.86
Bone mineral density and quantitative ultrasound in adults with cystic fibrosis. Eur J Endocrinol (2002) 0.85
CD14 expression and soluble CD14 after segmental allergen provocation in atopic asthma. Eur Respir J (1998) 0.85
Prostacyclin modulates granulocyte/macrophage colony-stimulating factor release by human blood mononuclear cells. Pulm Pharmacol (1996) 0.85
[A new biopsy needle for transcutaneous histology procurement]. Schweiz Med Wochenschr (1987) 0.85
[Aerosol therapy]. Prax Klin Pneumol (1988) 0.84
[Comparison of the antitussive effect of two different drugs regarding frequency and strength of cough attacks (author's transl)]. Med Klin (1977) 0.84
Bronchoalveolar lavage cell data in alveolar proteinosis. Am Rev Respir Dis (1991) 0.84
[Physical training of patients with sleep apnea]. Pneumologie (1997) 0.84
Pulmonary deposition of aerosols by different mechanical devices. Respiration (1985) 0.84
The immunoperoxidase slide assay. A new method for the demonstration of surface antigens on bronchoalveolar lavage cells. Bull Eur Physiopathol Respir (1985) 0.83
Normocapnia during nIPPV in chronic hypercapnic COPD reduces subsequent spontaneous PaCO2. Respir Med (2002) 0.83
Differential regulation of CD95 (Fas/APO-1) expression in human blood eosinophils. Eur J Immunol (1998) 0.83
Mucociliary clearance in patients with chronic bronchitis and bronchial carcinoma. Respiration (1983) 0.82
[Epidemiology and costs of bronchial asthma and chronic bronchitis in Germany]. Dtsch Med Wochenschr (2001) 0.82
Effects of TGF-beta on eosinophil chemotaxis. Scand J Immunol (1998) 0.82
CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur Respir J (1999) 0.81
Ca(2+)-channel blockers modulate expression of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and low density lipoprotein receptor genes stimulated by platelet-derived growth factor. Proc Natl Acad Sci U S A (1991) 0.81
Interferon-gamma secretion of peripheral blood CD8+ T lymphocytes in patients with bronchial asthma: in vitro stimulus determines cytokine production. Clin Exp Immunol (2001) 0.80
Differential modulation of interleukin-4 and interleukin-13 secretion from human peripheral blood mononuclear cells. Immunol Lett (1999) 0.80
[Critical selection of normal values for a computer program in the evaluation of lung function (author's transl)]. Pneumonologie (1976) 0.80
[Methodologic study for measuring oronasal airflow using thermistors]. Pneumologie (1989) 0.80
[Additive action of theophylline and ambroxol on bronchial clearance?]. Prax Klin Pneumol (1988) 0.80
Modulatory role of protein kinase C on the signal transduction pathway utilized by platelet-activating factor in eosinophil activation. Am J Respir Cell Mol Biol (1994) 0.79
Pulmonary sarcoidosis: assessment of disease activity by lung lymphocyte subpopulations. Klin Wochenschr (1983) 0.79
HLA-DR antigens on human macrophages from bronchoalveolar lavage fluid. Thorax (1986) 0.79
Antiasthma drug delivery. What is on the horizon? Clin Pharmacokinet (1994) 0.79
Analysis of forced expired volume signals using multi-exponential functions. Med Biol Eng Comput (2001) 0.79
[Effect of celiprolol, fenoterol and aminophylline on respiratory tract obstruction during an asthma attack]. Schweiz Med Wochenschr (1982) 0.79
Modulation of cytokine release from mononuclear cells by prostacyclin, IL-4 and IL-13. Cytokine (1999) 0.79
Mucociliary clearance and airways obstruction in smokers, ex-smokers and normal subjects who never smoked. Eur J Respir Dis Suppl (1985) 0.79
Inhibition of HLA-DR expression on activated human blood eosinophils by transforming growth factor-beta1. Scand J Immunol (1998) 0.79
[Epidemiology and costs of lung cancer in Germany]. Pneumologie (2001) 0.78
Cytokines, platelet activating factor and eosinophils in asthma. Respir Med (1992) 0.78
Comparison of sputum-ECP levels in bronchial asthma and chronic bronchitis. Allergy (1993) 0.78
Morphology and density features of eosinophil leukocytes in eosinophilic pneumonia. A case report. Clin Investig (1992) 0.78
Diagnosis by bronchoalveolar lavage of cause of pulmonary infiltrates in haematological malignancies. Br Med J (Clin Res Ed) (1985) 0.78
Effect of theophylline on mucociliary clearance in man. Eur J Respir Dis Suppl (1980) 0.78
Multinucleated cells in bronchoalveolar lavage. Acta Cytol (1985) 0.78
Bronchosparing properties of celiprolol, a new beta 1, alpha 2-blocker, in propranolol-sensitive asthmatic patients. J Cardiovasc Pharmacol (1986) 0.78
Evidence of PAF release and platelet activation in analgesics-asthma-syndrome. Agents Actions Suppl (1987) 0.77
The bronchosparing effect of celiprolol, a new beta 1- alpha 2-receptor antagonist on pulmonary function of propranolol-sensitive asthmatics. J Clin Pharmacol (1985) 0.77
[The connections between smoking, mucociliary clearance and airway obstruction]. Fortschr Med (1984) 0.77
[Effect of almitrine, a chemoreceptor stimulator, on nocturnal hypercapnia and pulmonary artery pressure during O2 respiration in chronic obstructive lung disease]. Prax Klin Pneumol (1988) 0.77
[Comparison of cardiac output at rest and during physical exertion using thermodilution and Fick's principle]. Schweiz Med Wochenschr (1973) 0.77
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker. Lung (1995) 0.77
[Scintigraphic radio-spirometry. Methods and indications]. Rofo (1975) 0.77
[Cardiopulmonary loading of aircraft passengers with obstructive ventilatory disorders]. Schweiz Med Wochenschr (1974) 0.76
[Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie (2001) 0.76
[Research on mucociliary clearence following administration of atrovent in healthy subjects and patients with chronic bronchitis]. Wien Med Wochenschr Suppl (1974) 0.76
Cellular and immunological markers of allergic and intrinsic bronchial asthma. Lung (1994) 0.76
Accuracy of nine commercially available pulse oximeters in monitoring patients with chronic respiratory insufficiency. Monaldi Arch Chest Dis (1994) 0.76
[Asthma therapy in children and adults. Comment on the contribution by Wettengel R., et al. Recommendations of the German Respiratory League in the German Society of Pneumology]. Med Klin (Munich) (1999) 0.75
Change in perforin-positive peripheral blood lymphocyte (PBL) subpopulations following exercise. Clin Exp Immunol (2000) 0.75
[Surfactant phospholipids in bronchoalveolar lavage fluid in smokers with healthy lungs and non-smokers]. Pneumologie (1990) 0.75
[Medical diving fitness clarification]. Schweiz Med Wochenschr (1970) 0.75
[Diagnosis of latent, manifest and decompensated cor pulmonale]. Verh Dtsch Ges Inn Med (1972) 0.75
[Hemodynamics and respiratory parameters in patients with pleural thickening]. Schweiz Med Wochenschr (1972) 0.75
[Occlusion volume in subjects exposed to asbestos]. Prax Pneumol (1974) 0.75
[The diagnostic value of measured functional parameters in obstructive lung diseases]. Helv Med Acta Suppl (1970) 0.75
[Modern pulmonary function tests: possibilities of regional functional diagnosis within the respiratory tract]. Med Monatsschr (1972) 0.75
[Investigation of the mucociliary clearance by means of 99mTc-labelled sulfur colloid (author's transl)]. Klin Wochenschr (1975) 0.75
Proceedings: Influence of secretolytic agents on mucociliary clearance in bronchitics. Bull Physiopathol Respir (Nancy) (1975) 0.75
Quantitative and selective bronchial clearance studies using 99 mTc-sulfate particles. Scand J Respir Dis Suppl (1974) 0.75
[The role of lung function tests in the diagnosis of respiratory diseases (author's transl)]. Prax Pneumol (1975) 0.75
[Testing of Eprazinone, a new drug with antiobstructive effect on the respiratory tract]. Med Welt (1975) 0.75
[An electronic digital spirometer (author's transl)]. Prax Pneumol (1975) 0.75
[Diagnosis of pulmonary function using nuclear medicine methods]. Schweiz Med Wochenschr (1972) 0.75
Ventilation-perfusion relationships studied with 133 xenon before and after bronchodilating drugs in patients with obstructive lung disease. Bull Physiopathol Respir (Nancy) (1973) 0.75
[Experience with hyperbaric oxygenation in man]. Schweiz Med Wochenschr (1970) 0.75
Effect of isosorbide dinitrate on hemodynamics and respiration of patients with coronary artery disease and of patients with chronic cor pulmonale. Respiration (1975) 0.75